More on SBFM
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1.11 |
|
|||
| Open | $1.14 | ||||
| 52 Wk High | $0.04 | ||||
| 52 Wk Low | $0.00 | ||||
| Day High | $1.14 | ||||
| Day Low | $1.11 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 82,958 | ||||
- Health Canada approves Sunshine Biopharma's generic Atenolol tablets
- Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions
- Form S-1 Sunshine Biopharma Inc.
- Form 8-K Sunshine Biopharma Inc. For: Aug 25
- A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
- Sunshine Biopharma reports tumor suppression results with K1.1 mRNA program
- Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer
- Sunshine Biopharma gets Canadian approval for generic Enalapril
- Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market
- Form SCHEDULE 13G/A Sunshine Biopharma Inc. Filed by: L1 Capital Global Opportunities Master Fund, Ltd.
Entities mentioned with SBFM
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- FDA | View Related Stories »
- S1 | View Related Stories »
- 13G | View Related Stories »
- Definitive Agreement | View Related Stories »
- NT 10-Q | View Related Stories »
- Show More...
